Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $3,271,795.52 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 154,768 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the transaction, the insider owned 221,278 shares of the company’s stock, valued at $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Friday, June 26th, Sharon Benzeno sold 11,034 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $21.00, for a total value of $231,714.00.

Adaptive Biotechnologies Trading Down 5.3%

Shares of Adaptive Biotechnologies stock opened at $21.19 on Friday. Adaptive Biotechnologies Corporation has a 52 week low of $9.96 and a 52 week high of $22.80. The stock has a market cap of $3.39 billion, a PE ratio of -64.21 and a beta of 2.07. The company’s 50-day moving average price is $15.95 and its two-hundred day moving average price is $15.83.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the firm earned ($0.20) EPS. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Morgan Stanley cut their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. JPMorgan Chase & Co. lowered their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. TD Cowen increased their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. raised its holdings in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $65,942,000. Geode Capital Management LLC increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after purchasing an additional 110,825 shares during the period. Finally, State Street Corp increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after purchasing an additional 102,362 shares during the period. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.